glp 1 receptor drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 The Impact of GLP-1 Receptor

In addition, the drug combination also had no effect on the intestinal microbiome in elderly patients with T2DM, but there was an increase in the percentage of bacteria of the genus Alistipes

GIP as a potential therapeutic target for atherosclerotic Cardiovascular Disease-A systematic review

What do GLP-1s actually do in the gut

Share your thoughts in the comments below, or start a conversation by posting on your Activities page

Methods Study design Representatives of the companies Bristol-Myers Squibb, Novo Nordisk, Sanofi, Merck, Novartis, Boehringer Ingelheim and Takeda were contacted with the request to provide the event numbers of acute pancreatitis with the respective drug and non-incretin comparators as well as the corresponding number of patient-years of exposure (PYOs) for the approved GLP-1 receptor agonists exenatide twice daily, exenatide weekly, liraglutide and lixisenatide, as well as the DPP-4 inhibitors sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin

This leads to increase in gastric volumes and putting the patients at increased risk of aspiration during sedation (107)